Actinium Pharmaceuticals (NYSE:ATNM) Downgraded to “Sell” at StockNews.com

Actinium Pharmaceuticals (NYSE:ATNM) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Monday.

Several other analysts have also recently commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Actinium Pharmaceuticals in a research note on Friday, July 26th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $21.00 price target on shares of Actinium Pharmaceuticals in a research note on Tuesday, April 30th. Finally, Stephens started coverage on shares of Actinium Pharmaceuticals in a research report on Tuesday, May 14th. They set an “overweight” rating and a $25.00 target price on the stock. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $25.60.

Actinium Pharmaceuticals Stock Performance

Shares of ATNM traded down $3.69 during trading hours on Monday, reaching $2.48. 15,825,064 shares of the stock traded hands, compared to its average volume of 406,230. The stock has a market cap of $73.86 million, a price-to-earnings ratio of -1.45 and a beta of 0.20. Actinium Pharmaceuticals has a 52-week low of $1.33 and a 52-week high of $10.24.

Institutional Trading of Actinium Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in ATNM. Sanders Morris Harris LLC acquired a new stake in Actinium Pharmaceuticals during the first quarter valued at $78,000. Rhumbline Advisers grew its position in Actinium Pharmaceuticals by 23.4% during the second quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock valued at $293,000 after buying an additional 7,525 shares during the period. Bank of New York Mellon Corp grew its position in Actinium Pharmaceuticals by 28.3% during the second quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock valued at $639,000 after buying an additional 19,035 shares during the period. Virtu Financial LLC grew its position in Actinium Pharmaceuticals by 319.2% during the first quarter. Virtu Financial LLC now owns 82,029 shares of the company’s stock valued at $642,000 after buying an additional 62,459 shares during the period. Finally, Vanguard Group Inc. grew its position in Actinium Pharmaceuticals by 6.0% during the first quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock valued at $11,325,000 after buying an additional 82,113 shares during the period. Institutional investors and hedge funds own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.